A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Inclusion Criteria: * First generation Japanese; subject was born in Japan and has not lived outside of Japan for \> 10 years, and subject can trace maternal and paternal Japanese ancestry. * Histologically confirmed aggressive/indolent DLBCL, FL, MZL, or MCL. * Previously received at least 1 prior line of systemic therapy with documented progression, and there is no further effective standard anticancer therapy available. * Willing to undergo an incisional or excisional lymph node or tissue biopsy or to provide a lymph node or tissue biopsy from the most recent available archival tissue. * Life expectancy \> 3 months. * Eastern Cooperative Oncology Group performance status of 0 to 2. * Adequate hematologic, hepatic, and renal function. Exclusion Criteria: * Evidence of transformed non-Hodgkin's lymphoma histologies. * Histologically confirmed, rare non-Hodgkin's B-cell subtypes. * History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease. * Prior treatment with idelalisib, other selective PI3Kδ inhibitors, or a pan-phosphatidylinositol 3 kinase (PI3K) inhibitor. * Allogeneic stem cell transplant within the last 6 months or autologous stem cell transplant within the last 3 months before the date of the first dose of study drug. * Active graft-versus-host disease. * History of stroke or intracranial hemorrhage within 6 months of study drug administration. * Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment or exposure to a live vaccine within 30 days of the date of the first dose of study drug. * Known human immunodeficiency virus infection. * Evidence of hepatitis B virus or hepatitis C virus infection or risk of reactivation.